Hi All, I haven't posted in awhile primarily because I am not a "Market/Buisness" guy but rather a clinical bedside manmagement provider in an ICU (United States). I have had a few "light hearted" discussions with some MDs and specialist from various fields on the topic of epigenetics. Most outside of the Heme/Onc realm are aware of this emerging therapeutic option but it is not something they devote any amount of time gathering an understanding about. When I asked if they would invest in a leading edge small cap bio, most replied basically "the science is still ambiguous" and they would not at this juncture. Only one of the six MDs was aware of RVX but doesn't follow them. Remeber these are clinians and not research oriented physicians. If it isn't in "Up-To-Date" they most likely are unaware.